ChemoMetec (CHY) Stock Overview
Engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
CHY Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
ChemoMetec A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 42.58 |
| 52 Week High | DKK 106.60 |
| 52 Week Low | DKK 33.74 |
| Beta | 1.36 |
| 1 Month Change | -20.26% |
| 3 Month Change | -54.94% |
| 1 Year Change | -32.68% |
| 3 Year Change | -8.23% |
| 5 Year Change | -53.44% |
| Change since IPO | 143.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| CHY | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 4.3% | 5.7% | 0.5% |
| 1Y | -32.7% | -6.9% | 8.5% |
Return vs Industry: CHY underperformed the German Life Sciences industry which returned -2.3% over the past year.
Return vs Market: CHY underperformed the German Market which returned 8.4% over the past year.
Price Volatility
| CHY volatility | |
|---|---|
| CHY Average Weekly Movement | 11.9% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 14.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: CHY's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CHY's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 172 | Martin Behrens | chemometec.com |
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer.
ChemoMetec A/S Fundamentals Summary
| CHY fundamental statistics | |
|---|---|
| Market cap | €769.72m |
| Earnings (TTM) | €23.68m |
| Revenue (TTM) | €65.97m |
Is CHY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHY income statement (TTM) | |
|---|---|
| Revenue | DKK 493.12m |
| Cost of Revenue | DKK 21.98m |
| Gross Profit | DKK 471.14m |
| Other Expenses | DKK 294.11m |
| Earnings | DKK 177.03m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Sep 10, 2026
| Earnings per share (EPS) | 10.17 |
| Gross Margin | 95.54% |
| Net Profit Margin | 35.90% |
| Debt/Equity Ratio | 0.2% |
How did CHY perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/15 04:51 |
| End of Day Share Price | 2026/04/15 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ChemoMetec A/S is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mads Brinkmann Andersen | Berenberg |
| Kallum Titchmarsh | BofA Global Research |
| Simon Larsson | Danske Bank |